246 related articles for article (PubMed ID: 29937176)
1. Characterization of adrenocortical tumors by
Paladino NC; Guérin C; Lowery A; Attard A; Essamet W; Slotema E; Morange I; Castinetti F; Brue T; Loundou A; Taïeb D; Sebag F
Surg Oncol; 2018 Jun; 27(2):231-235. PubMed ID: 29937176
[TBL] [Abstract][Full Text] [Related]
2. Predicting malignancy in patients with adrenal tumors using
Vos EL; Grewal RK; Russo AE; Reidy-Lagunes D; Untch BR; Gavane SC; Boucai L; Geer E; Gopalan A; Chou JF; Capanu M; Strong VE
J Surg Oncol; 2020 Dec; 122(8):1821-1826. PubMed ID: 32914407
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
4. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning.
Nunes ML; Rault A; Teynie J; Valli N; Guyot M; Gaye D; Belleannee G; Tabarin A
World J Surg; 2010 Jul; 34(7):1506-10. PubMed ID: 20396886
[TBL] [Abstract][Full Text] [Related]
6. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
[TBL] [Abstract][Full Text] [Related]
7. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
[TBL] [Abstract][Full Text] [Related]
8. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
[TBL] [Abstract][Full Text] [Related]
9. The computed tomography adrenal wash-out analysis properly classifies cortisol secreting adrenocortical adenomas.
Humbert AL; Lecoanet G; Moog S; Bouderraoui F; Bresler L; Vignaud JM; Chevalier E; Brunaud L; Klein M; Cuny T
Endocrine; 2018 Mar; 59(3):529-537. PubMed ID: 29332161
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas.
Moreau A; Giraudet AL; Kryza D; Borson-Chazot F; Bournaud C; Mognetti T; Lifante JC; Combemale P; Giammarile F; Houzard C
Nucl Med Commun; 2017 Sep; 38(9):771-779. PubMed ID: 28704339
[TBL] [Abstract][Full Text] [Related]
11. Preoperative 18F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors.
Gust L; Taieb D; Beliard A; Barlier A; Morange I; de Micco C; Henry JF; Sebag F
World J Surg; 2012 Jun; 36(6):1406-10. PubMed ID: 22131094
[TBL] [Abstract][Full Text] [Related]
12. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
13. The value of 18F-FDG PET-CT and 131I-norcholesterol scintigraphy in the characterization of high-risk adrenal masses.
Riaz S; Syed R; Aziz TA; Alnaim A; Chung TT; Wan S; Kurzawinski TR; Bomanji J
Nucl Med Commun; 2020 Mar; 41(3):189-195. PubMed ID: 31895761
[TBL] [Abstract][Full Text] [Related]
14. Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy.
Leboulleux S; Deandreis D; Escourrou C; Al Ghuzlan A; Bidault F; Aupérin A; Travagli JP; Lumbroso J; Schlumberger M; Baudin E
Eur J Endocrinol; 2011 Jan; 164(1):89-94. PubMed ID: 20921280
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value.
Tessonnier L; Ansquer C; Bournaud C; Sebag F; Mirallié E; Lifante JC; Palazzo FF; Morange I; Drui D; de la Foucardère C; Mancini J; Taïeb D
World J Surg; 2013 Jan; 37(1):107-12. PubMed ID: 23001287
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.
Ardito A; Massaglia C; Pelosi E; Zaggia B; Basile V; Brambilla R; Vigna-Taglianti F; Duregon E; Arena V; Perotti P; Penna D; Terzolo M
Eur J Endocrinol; 2015 Dec; 173(6):749-56. PubMed ID: 26346137
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of
Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
[TBL] [Abstract][Full Text] [Related]
18. Genetic status determines
Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
[TBL] [Abstract][Full Text] [Related]
19. Adrenal findings in FDG-PET: analysis of a cohort of 1021 patients from a cancer center.
Maciel J; Cavaco D; Fraga D; Donato S; Simões H; Sousa R; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):131-138. PubMed ID: 36477790
[TBL] [Abstract][Full Text] [Related]
20. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG.
Minn H; Salonen A; Friberg J; Roivainen A; Viljanen T; Långsjö J; Salmi J; Välimäki M; Någren K; Nuutila P
J Nucl Med; 2004 Jun; 45(6):972-9. PubMed ID: 15181132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
